Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: Week 60 results from the PACTG 381 cohort

被引:27
作者
Rudy, BJ
Lindsey, JC
Flynn, PM
Bosch, RJ
Wilson, CM
Hughes, ME
Douglas, SD
机构
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[4] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[5] Univ Alabama Birmingham, Birmingham, AL 35294 USA
关键词
D O I
10.1089/aid.2006.22.213
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The responses to HAART in HIV-infected adolescents infected through risk behaviors are not well defined. PACTG 381 collected intensive immunologic and virologic data on youth naive to or with minimal exposure to antiretroviral therapy who began HAART. Subjects were evaluated according to their weeks 16-24 virologic response. Comparisons with a cohort of HIV-uninfected adolescents from the REACH cohort were performed. Cox proportional hazards models were used to identify baseline and week 24 predictors of virologic failure. Only 69 of 120 subjects (58%) achieved virologic suppression by weeks 16-24, whereas 55 of 69 (80%) demonstrated control to week 60. Higher CD4(+) naive T cells (CD4(+)/62L(+)/RA(+): hazard ratio [HR], 2.13; p = 0.018), higher CD8(+) activated T cells (CD8(+)/CD38(+)/DR+: HR, 1.40, p = 0.028 per 100 cells/mm(3)) and higher CD8(+) naive T cells (CD8(+)/62L(+)/RA(+): HR, 1.72; p = 0.005) at weeks 16-24 in subjects with early viral success were predictive of subsequent failure. By week 60, total CD4(+) T cells remained significantly lower than in uninfected controls. Adolescents beginning HAART achieve moderate rates of viral suppression by weeks 16-24. In those who do achieve early virologic control, suppression to week 60 is high although total CD4(+) T cells remain significantly lower than in uninfected controls. Several T cell markers were predictive of subsequent virologic failure in subjects achieving short-term success. Further study is warranted to determine whether these predictors provide any benefit to clinical management.
引用
收藏
页码:213 / 221
页数:9
相关论文
共 39 条
[1]  
[Anonymous], GUID US ANT AG HIV 1
[2]   Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users [J].
Carbone, J ;
Gil, J ;
Benito, JM ;
Navarro, J ;
Muñóz-Fernández, A ;
Bartolomé, J ;
Zabay, JM ;
López, F ;
Fernández-Cruz, E .
AIDS, 2000, 14 (18) :2823-2829
[3]  
*CDCP, YOUNG PEOPL RISK HIV
[4]   Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy [J].
Clerici, M ;
Saresella, M ;
Trabattoni, D ;
Ferrante, P ;
Vanzulli, A ;
Vigano, A .
AIDS, 2002, 16 (16) :2219-2221
[5]   Immune activation set point during early FHV infection predicts subsequent CD4+ T-cell changes independent of viral load [J].
Deeks, SG ;
Kitchen, CMR ;
Liu, L ;
Guo, H ;
Gascon, R ;
Narváez, AB ;
Hunt, P ;
Martin, JN ;
Kahn, JO ;
Levy, J ;
McGrath, MS ;
Hecht, FM .
BLOOD, 2004, 104 (04) :942-947
[6]   Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents [J].
Douglas, SD ;
Rudy, B ;
Muenz, L ;
Moscicki, AB ;
Wilson, CM ;
Holland, C ;
Crowley-Nowick, P ;
Vermund, SH .
AIDS, 1999, 13 (13) :1629-1635
[7]   T-lymphocyte subsets in HIV-infected and high-risk HIV-uninfected adolescents -: Retention of naive T lymphocytes in HIV-infected adolescents [J].
Douglas, SD ;
Rudy, B ;
Muenz, L ;
Starr, SE ;
Campbell, DE ;
Wilson, C ;
Holland, C ;
Crowley-Nowick, P ;
Vermund, SH .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2000, 154 (04) :375-380
[8]   Guidelines for using antiretroviral agents among HIV-infected adults and adolescents - The panel on clinical practices for treatment of HIV [J].
Dybul, M ;
Fauci, AS ;
Bartlett, JG ;
Kaplan, JE ;
Pau, AK .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (05) :381-433
[9]   Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy [J].
Flynn, PM ;
Rudy, BJ ;
Douglas, SD ;
Lathey, J ;
Spector, SA ;
Martinez, J ;
Silio, M ;
Belzer, M ;
Friedman, L ;
D'Angelo, L ;
McNamara, J ;
Hodge, J ;
Hughes, MD ;
Lindsey, JC .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (02) :271-279
[10]   T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy [J].
Franco, JM ;
Rubio, A ;
Martínez-Moya, M ;
Leal, M ;
Merchante, E ;
Sánchez-Quijano, A ;
Lissen, E .
BLOOD, 2002, 99 (10) :3702-3706